BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000. [PMID: 8247075 DOI: 10.1056/NEJM199312303292704] [Cited by in Crossref: 794] [Cited by in F6Publishing: 816] [Article Influence: 26.5] [Reference Citation Analysis]
Number Citing Articles
1 Casal-Dominguez M, Pinal-Fernandez I, Pak K, Muñoz-Braceras S, Milisenda JC, Torres-Ruiz J, Dell Orso S, Naz F, Gutierrez-Cruz G, Duque-Jaimez Y, Matas-Garcia A, Valls-Roca L, Garrabou G, Trallero-Araguas E, Walitt B, Christopher-Stine L, Lloyd TE, Paik JJ, Albayda J, Corse A, Grau JM, Selva-O'Callaghan A, Mammen AL. Coordinated local RNA overexpression of complement induced by interferon gamma in myositis. Sci Rep 2023;13:2038. [PMID: 36739295 DOI: 10.1038/s41598-023-28838-z] [Reference Citation Analysis]
2 Giannini M, Ellezam B, Leclair V, Lefebvre F, Troyanov Y, Hudson M, Senécal J, Geny B, Landon-cardinal O, Meyer A. Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis. Front Immunol 2023;13. [DOI: 10.3389/fimmu.2022.974078] [Reference Citation Analysis]
3 Manousakis G. Inflammatory Myopathies. Continuum (Minneap Minn) 2022;28:1643-62. [PMID: 36537973 DOI: 10.1212/CON.0000000000001179] [Reference Citation Analysis]
4 Yang L, Wei X, Li Q, Li H, Ouyang Z, Zeng A, Zheng D, Dai L, Mo Y. Transient positive antimitochondrial M2 in sera of patients with connective tissue diseases after intravenous immunoglobulin infusions. Rheumatology & Autoimmunity 2022. [DOI: 10.1002/rai2.12050] [Reference Citation Analysis]
5 Alnoukari M, De La Garza OG, Al Gburi K, Patel N, Lopez H, Shamim M, Kwang H. IVIG for refractory dysphagia in Antisynthetase syndrome: A truth hard to swallow. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.6569] [Reference Citation Analysis]
6 Dalakas MC, Latov N, Kuitwaard K. Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): mechanisms of action and clinical and genetic considerations. Expert Rev Neurother 2022;22:953-62. [PMID: 36645654 DOI: 10.1080/14737175.2022.2169134] [Reference Citation Analysis]
7 Günther C. Tumorscreening obligatorisch. Dtsch Dermatolog 2022;70:886-895. [DOI: 10.1007/s15011-022-5635-1] [Reference Citation Analysis]
8 Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Csörgő Z, Dimachkie MM, Griger Z, Moiseev S, Oddis C, Schiopu E, Vencovský J, Beckmann I, Clodi E, Bugrova O, Dankó K, Ernste F, Goyal NA, Heuer M, Hudson M, Hussain YM, Karam C, Magnolo N, Nelson R, Pozur N, Prystupa L, Sárdy M, Valenzuela G, van der Kooi AJ, Vu T, Worm M, Levine T; ProDERM Trial Group. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med 2022;387:1264-78. [PMID: 36198179 DOI: 10.1056/NEJMoa2117912] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Mano T, Soyama S, Sugie K. Improvement in Tongue Pressure Precedes Improvement in Dysphagia in Dermatomyositis. Clinics and Practice 2022;12:797-802. [DOI: 10.3390/clinpract12050083] [Reference Citation Analysis]
10 Chung MP, Paik JJ. Past, Present, and Future in Dermatomyositis Therapeutics. Curr Treat Options in Rheum. [DOI: 10.1007/s40674-022-00193-6] [Reference Citation Analysis]
11 Davuluri S, Duvvuri B, Lood C, Faghihi-Kashani S, Chung L. Calcinosis in dermatomyositis: Origins and possible therapeutic avenues. Best Pract Res Clin Rheumatol 2022;:101768. [PMID: 35803868 DOI: 10.1016/j.berh.2022.101768] [Reference Citation Analysis]
12 Dalakas MC, Dalmau J. Comment: Humoral and T-cell Immunities to SARS-CoV-2 Vaccines: Safety, Efficacy, and Challenges in Autoimmune Neurology. Neurol Neuroimmunol Neuroinflamm 2022;9:e200010. [DOI: 10.1212/nxi.0000000000200010] [Reference Citation Analysis]
13 Connolly CM, Plomp L, Paik JJ, Allenbach Y. Possible future avenues for myositis therapeutics: DM, IMNM and IBM. Best Pract Res Clin Rheumatol 2022;:101762. [PMID: 35778272 DOI: 10.1016/j.berh.2022.101762] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Dalakas MC. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Rev Clin Immunol 2022;:1-11. [PMID: 35730504 DOI: 10.1080/1744666X.2022.2082946] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
15 De León AM, Harrison TB, Garcia-santibanez R. Update on Paraneoplastic Neuromuscular Disorders. Curr Treat Options Neurol 2022;24:267-84. [DOI: 10.1007/s11940-022-00722-7] [Reference Citation Analysis]
16 Dressler F, Maurer B. [Dermatomyositis and juvenile dermatomyositis]. Z Rheumatol 2022. [PMID: 35486206 DOI: 10.1007/s00393-022-01205-5] [Reference Citation Analysis]
17 Danieli MG, Tonacci A, Paladini A, Longhi E, Moroncini G, Allegra A, Sansone F, Gangemi S. A machine learning analysis to predict the response to intravenous and subcutaneous immunoglobulin in inflammatory myopathies. A proposal for a future multi-omics approach in autoimmune diseases. Autoimmun Rev 2022;:103105. [PMID: 35452850 DOI: 10.1016/j.autrev.2022.103105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Kamperman RG, van der Kooi AJ, de Visser M, Aronica E, Raaphorst J. Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review. Int J Mol Sci 2022;23:4301. [PMID: 35457124 DOI: 10.3390/ijms23084301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Zeng R, Glaubitz S, Schmidt J. Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options. Neurotherapeutics 2022. [PMID: 35394612 DOI: 10.1007/s13311-022-01220-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Dalakas MC. Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits. Expert Rev Clin Immunol 2022;:1-11. [PMID: 35323101 DOI: 10.1080/1744666X.2022.2054803] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Qian J, Xu H. COVID-19 Disease and Dermatomyositis: A Mini-Review. Front Immunol 2021;12:747116. [PMID: 35095837 DOI: 10.3389/fimmu.2021.747116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
22 Danieli MG, Verga JU, Mezzanotte C, Terrenato I, Svegliati S, Bilo MB, Moroncini G. Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients. Front Immunol 2021;12:805705. [PMID: 35111165 DOI: 10.3389/fimmu.2021.805705] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Mazori DR, Femia AN. Reactive Erythemas and Panniculitides in Connective Tissue Disease. Interdisciplinary Approaches to Overlap Disorders in Dermatology & Rheumatology 2022. [DOI: 10.1007/978-3-319-18446-3_10] [Reference Citation Analysis]
24 Andersen BM, Reardon DA. Neurologic complications of immune modulatory therapy. Neurological Complications of Systemic Cancer and Antineoplastic Therapy 2022. [DOI: 10.1016/b978-0-12-821976-8.00025-6] [Reference Citation Analysis]
25 Salazar-villa G, Rodríguez-prada C, Bonfante-tamara M, Restrepo-correa R, Rodríguez-padilla LM, Mesa-navas MA, Velásquez-franco CJ. Clinical characterization of patients with inflammatory myopathy in 2 tertiary care hospitals in Colombia: A descriptive survey. Revista Colombiana de Reumatología (English Edition) 2022;29:9-18. [DOI: 10.1016/j.rcreue.2020.09.005] [Reference Citation Analysis]
26 Salazar-villa G, Rodríguez-prada C, Bonfante-tamara M, Restrepo-correa R, Rodríguez-padilla LM, Mesa-navas MA, Velásquez-franco CJ. Caracterización clínica de pacientes con miopatía inflamatoria en 2 instituciones de alta complejidad en Colombia: estudio descriptivo. Revista Colombiana de Reumatología 2022;29:9-18. [DOI: 10.1016/j.rcreu.2020.09.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Goswami RP, Kumar U. Biologics in Idiopathic Inflammatory Myopathies. Handbook of Biologics for Rheumatological Disorders 2022. [DOI: 10.1007/978-981-16-7200-2_9] [Reference Citation Analysis]
28 Dalakas MC. IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti-B Cell Therapies. Neurol Neuroimmunol Neuroinflamm 2022;9:e1116. [PMID: 34845096 DOI: 10.1212/NXI.0000000000001116] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
29 Lewis M, Chung L, Fiorentino D. Dermatomyositis. Interdisciplinary Approaches to Overlap Disorders in Dermatology & Rheumatology 2022. [DOI: 10.1007/978-3-319-18446-3_4] [Reference Citation Analysis]
30 Dalakas MC. Treatment and Management of Autoimmune Myopathies. Neuromuscular Disorders 2022. [DOI: 10.1016/b978-0-323-71317-7.00022-6] [Reference Citation Analysis]
31 Chalayer E, Gramont B, Zekre F, Goguyer-Deschaumes R, Waeckel L, Grange L, Paul S, Chung AW, Killian M. Fc receptors gone wrong: A comprehensive review of their roles in autoimmune and inflammatory diseases. Autoimmun Rev 2021;21:103016. [PMID: 34915182 DOI: 10.1016/j.autrev.2021.103016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, Mammen AL, Miller FW. Idiopathic inflammatory myopathies. Nat Rev Dis Primers 2021;7:86. [PMID: 34857798 DOI: 10.1038/s41572-021-00321-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 48] [Article Influence: 20.5] [Reference Citation Analysis]
33 Varadhachary AS. Recognition and Management of Neuromuscular Emergencies. Neurol Clin 2022;40:157-74. [PMID: 34798967 DOI: 10.1016/j.ncl.2021.08.010] [Reference Citation Analysis]
34 Uruha A. Autoimmune myositis—Mechanism and therapy development. Neurol Clin Neurosci 2021. [DOI: 10.1111/ncn3.12563] [Reference Citation Analysis]
35 Goswami RP, Haldar SN, Chatterjee M, Vij P, van der Kooi AJ, Lim J, Raaphorst J, Bhadu D, Gelardi C, Danieli MG, Kumar U. Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: A systematic review and meta-analysis. Autoimmun Rev 2021;:102997. [PMID: 34800685 DOI: 10.1016/j.autrev.2021.102997] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Zeng R, Glaubitz S, Schmidt J. Inflammatory myopathies: shedding light on promising agents and combination therapies in clinical trials. Expert Opin Investig Drugs 2021;30:1125-40. [PMID: 34779311 DOI: 10.1080/13543784.2021.2003776] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Dalakas MC. Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy. Neurotherapeutics 2021. [PMID: 34766257 DOI: 10.1007/s13311-021-01108-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
38 Ruiz-Lozano RE, Velazquez-Valenzuela F, Roman-Zamudio M, Andrade-Leal SK, Rodriguez-Garcia A. Polymyositis and dermatomyositis: ocular manifestations and potential sight-threatening complications. Rheumatol Int 2021. [PMID: 34674015 DOI: 10.1007/s00296-021-05035-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Unger L. Therapieoptionen und outcome bei idiopathischen entzündlichen Muskelerkrankungen. Aktuelle Rheumatologie 2021;46:388-99. [DOI: 10.1055/a-1423-7579] [Reference Citation Analysis]
40 Sunderkötter C, Golle L. Dermatologische Differentialdiagnosen von idiopathischen entzündlichen Muskelerkrankungen. Aktuelle Rheumatologie 2021;46:382-7. [DOI: 10.1055/a-1551-5556] [Reference Citation Analysis]
41 Farini A, Villa C, Tripodi L, Legato M, Torrente Y. Role of Immunoglobulins in Muscular Dystrophies and Inflammatory Myopathies. Front Immunol 2021;12:666879. [PMID: 34335568 DOI: 10.3389/fimmu.2021.666879] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Stathopoulos P, Dalakas MC. Autoimmune Neurogenic Dysphagia. Dysphagia 2021. [PMID: 34226958 DOI: 10.1007/s00455-021-10338-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Soutif C, Tison T, Focant I, Seront E. Severe polymyositis occurring in a cancer patient directly after chemotherapy: etiology and management. Future Sci OA 2021;7:FSO706. [PMID: 34211735 DOI: 10.2144/fsoa-2021-0011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Lim J, Eftimov F, Verhamme C, Brusse E, Hoogendijk JE, Saris CGJ, Raaphorst J, De Haan RJ, van Schaik IN, Aronica E, de Visser M, van der Kooi AJ. Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study. Rheumatology (Oxford) 2021;60:1784-92. [PMID: 33099648 DOI: 10.1093/rheumatology/keaa459] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
45 Shahin AA, Niazy MH, Haroon MM. Response to cyclophosphamide and rituximab therapy in idiopathic inflammatory myopathies: A single center experience. The Egyptian Rheumatologist 2021;43:247-251. [DOI: 10.1016/j.ejr.2021.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Malartre S, Bachasson D, Mercy G, Sarkis E, Anquetil C, Benveniste O, Allenbach Y. MRI and muscle imaging for idiopathic inflammatory myopathies. Brain Pathol 2021;31:e12954. [PMID: 34043260 DOI: 10.1111/bpa.12954] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
47 Dalakas MC, Spaeth PJ. The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord 2021;14:1756286421997381. [PMID: 33717213 DOI: 10.1177/1756286421997381] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
48 Orgeron R. Complications of refractory juvenile dermatomyositis: a case report and literature review. MOJCR 2021;11:8-12. [DOI: 10.15406/mojcr.2021.11.00371] [Reference Citation Analysis]
49 Almoallim H, Albar H, Mehdawi F. Diagnostic Approach to Proximal Myopathy. Skills in Rheumatology 2021. [DOI: 10.1007/978-981-15-8323-0_9] [Reference Citation Analysis]
50 Macaron G, Willis MA. Concepts of Immune Therapy and Disease Management. Neuroimmunology 2021. [DOI: 10.1007/978-3-030-61883-4_5] [Reference Citation Analysis]
51 Sulk M, Goerge T, Luger TA. Intravenous Immunoglobulin Therapy. Comprehensive Dermatologic Drug Therapy 2021. [DOI: 10.1016/b978-0-323-61211-1.00036-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Pabolu S, Dudekula A, Pitchumoni CS. Gastrointestinal Manifestations of Non-GI Disorders. Geriatric Gastroenterology 2021. [DOI: 10.1007/978-3-030-30192-7_86] [Reference Citation Analysis]
53 Findlay AR, Bucelli RC. Immune and Inflammatory Myopathies. Neuroimmunology 2021. [DOI: 10.1007/978-3-030-61883-4_20] [Reference Citation Analysis]
54 Pabolu S, Dudekula A, Pitchumoni CS. Gastrointestinal Manifestations of Non-GI Disorders. Geriatric Gastroenterology 2021. [DOI: 10.1007/978-3-319-90761-1_86-1] [Reference Citation Analysis]
55 Stoevesandt J, Heitmann J, Goebeler M, Benoit S. Neutropenie als Nebenwirkung der Therapie mit hochdosierten intravenösen Immunglobulinen in der Dermatologie. J Dtsch Dermatol Ges 2020;18:1394-404. [PMID: 33373142 DOI: 10.1111/ddg.14310_g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Stoevesandt J, Heitmann J, Goebeler M, Benoit S. Neutropenia resulting from high-dose intravenous immunoglobulin in dermatological patients. J Dtsch Dermatol Ges 2020;18:1394-403. [PMID: 33373152 DOI: 10.1111/ddg.14310] [Reference Citation Analysis]
57 Dalakas MC. Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications. Acta Myol 2020;39:289-301. [PMID: 33458584 DOI: 10.36185/2532-1900-032] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
58 Odales J, Guzman Valle J, Martínez-Cortés F, Manoutcharian K. Immunogenic properties of immunoglobulin superfamily members within complex biological networks. Cell Immunol 2020;358:104235. [PMID: 33137645 DOI: 10.1016/j.cellimm.2020.104235] [Reference Citation Analysis]
59 Peshbahar S, Bendstrup E. Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease. Eur Clin Respir J 2020;7:1840706. [PMID: 33224454 DOI: 10.1080/20018525.2020.1840706] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol 2020;16:601-17. [PMID: 33005040 DOI: 10.1038/s41582-020-0400-0] [Cited by in Crossref: 70] [Cited by in F6Publishing: 76] [Article Influence: 23.3] [Reference Citation Analysis]
61 Schlecht N, Sunderkötter C, Niehaus S, Nashan D. Update on dermatomyositis in adults. J Dtsch Dermatol Ges 2020;18:995-1013. [PMID: 32985813 DOI: 10.1111/ddg.14267] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
62 Schlecht N, Sunderkötter C, Niehaus S, Nashan D. Adulte Form der Dermatomyositis - ein Update. J Dtsch Dermatol Ges 2020;18:995-1014. [PMID: 32985818 DOI: 10.1111/ddg.14267_g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
63 Smith LN, Paik JJ. Promising and Upcoming Treatments in Myositis. Curr Rheumatol Rep 2020;22:65. [PMID: 32845402 DOI: 10.1007/s11926-020-00943-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
64 Khadilkar SV, Dhamne MC. What is New in Idiopathic Inflammatory Myopathies: Mechanisms and Therapies. Ann Indian Acad Neurol 2020;23:458-67. [PMID: 33223661 DOI: 10.4103/aian.AIAN_400_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
65 Cobos GA, Femia A, Vleugels RA. Dermatomyositis: An Update on Diagnosis and Treatment. Am J Clin Dermatol 2020;21:339-53. [PMID: 32096127 DOI: 10.1007/s40257-020-00502-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 8.7] [Reference Citation Analysis]
66 Hadaschik E, Eming R, French LE, Girolomoni G, Hertl M, Jolles S, Karpati S, Steinbrink K, Stingl G, Volc-Platzer B, Zillikens D, Enk A. [European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology]. Hautarzt 2020;71:542-52. [PMID: 32435817 DOI: 10.1007/s00105-020-04610-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
67 Solimando AG, Crudele L, Leone P, Argentiero A, Guarascio M, Silvestris N, Vacca A, Racanelli V. Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside. Int J Mol Sci 2020;21:E3054. [PMID: 32357515 DOI: 10.3390/ijms21093054] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
68 Shinjo SK, de Souza FHC. Treatment options from bench to bedside for adult dermatomyositis. Expert Opinion on Orphan Drugs 2020;8:91-9. [DOI: 10.1080/21678707.2020.1742695] [Reference Citation Analysis]
69 Patwardhan A. The Value of Intravenous Immunoglobulin Therapy in Idiopathic Inflammatory Myositis in the Current Transformed Era of Biologics. Cureus 2020;12:e7049. [PMID: 32128294 DOI: 10.7759/cureus.7049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
70 Çağlayan M, Işik H, Oktayoglu P. A Case of Refractory Polymyositis Successfully Treated With Abatacept Monotherapy. Arch Rheumatol 2020;35:618-22. [PMID: 33758820 DOI: 10.46497/ArchRheumatol.2020.7406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 Kwan C, Milosevic S, Benham H, Scott IA. A rare form of dermatomyositis associated with muscle weakness and normal creatine kinase level. BMJ Case Rep 2020;13:e232260. [PMID: 32033996 DOI: 10.1136/bcr-2019-232260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
72 Allenbach Y, Benveniste O. Miopatie infiammatorie. EMC - Neurologia 2020;20:1-13. [DOI: 10.1016/s1634-7072(20)43301-x] [Reference Citation Analysis]
73 Das M, Karnam A, Stephen-Victor E, Gilardin L, Bhatt B, Kumar Sharma V, Rambabu N, Patil V, Lecerf M, Käsermann F, Bruneval P, Narayanaswamy Balaji K, Benveniste O, Kaveri SV, Bayry J. Intravenous immunoglobulin mediates anti-inflammatory effects in peripheral blood mononuclear cells by inducing autophagy. Cell Death Dis 2020;11:50. [PMID: 31974400 DOI: 10.1038/s41419-020-2249-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
74 Glaubitz S, Zeng R, Schmidt J. New insights into the treatment of myositis. Ther Adv Musculoskelet Dis 2020;12:1759720X19886494. [PMID: 31949477 DOI: 10.1177/1759720X19886494] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
75 Dvergsten J, Reed A. Management Considerations: Juvenile Dermatomyositis. Managing Myositis 2020. [DOI: 10.1007/978-3-030-15820-0_30] [Reference Citation Analysis]
76 Lewis MA, Fiorentino DF. Management Considerations: Refractory Skin Rash and Calcinosis. Managing Myositis 2020. [DOI: 10.1007/978-3-030-15820-0_31] [Reference Citation Analysis]
77 Oddis CV, Aggarwal R. Management Considerations: Pharmacologic Intervention. Managing Myositis 2020. [DOI: 10.1007/978-3-030-15820-0_29] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Tiong BK, Hahn BH, Aung T. Treatment of Autoimmune Disease: Established Therapies. The Autoimmune Diseases 2020. [DOI: 10.1016/b978-0-12-812102-3.00071-3] [Reference Citation Analysis]
79 Solimani F, Meier K, Ghoreschi K. Emerging Topical and Systemic JAK Inhibitors in Dermatology. Front Immunol 2019;10:2847. [PMID: 31849996 DOI: 10.3389/fimmu.2019.02847] [Cited by in Crossref: 100] [Cited by in F6Publishing: 104] [Article Influence: 25.0] [Reference Citation Analysis]
80 Yang SH, Chang C, Lian ZX. Polymyositis and dermatomyositis - challenges in diagnosis and management. J Transl Autoimmun 2019;2:100018. [PMID: 32743506 DOI: 10.1016/j.jtauto.2019.100018] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
81 Hellmich B, Löffler C. [What are the indications for rescue procedures? : Systemic rheumatic diseases in the intensive care unit]. Z Rheumatol 2019;78:955-66. [PMID: 31485728 DOI: 10.1007/s00393-019-00687-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
82 Hoffmann JHO, Enk AH. High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease. Front Immunol 2019;10:1090. [PMID: 31244821 DOI: 10.3389/fimmu.2019.01090] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
83 Wolstencroft PW, Chung L, Li S, Casciola-Rosen L, Fiorentino DF. Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis. JAMA Dermatol 2018;154:44-51. [PMID: 29114741 DOI: 10.1001/jamadermatol.2017.3758] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
84 Cembrero-saralegui H, Fernández-cogolludo E, Vargas-laguna E. Prurito incoercible en dermatomiositis paraneoplásica. ¿Qué podemos hacer? Piel 2019;34:276-278. [DOI: 10.1016/j.piel.2018.05.005] [Reference Citation Analysis]
85 Nikitin SS, Boriskina LM. Immunoglobulins in neurological practice: a review of the literature. Neuromuscular Diseases 2019;9:32-51. [DOI: 10.17650/2222-8721-2019-9-1-32-51] [Reference Citation Analysis]
86 Göbel M. 66/m mit lividem Gesichtserythem, Nagelfalzhyperkeratosen und Abgeschlagenheit. Hautarzt 2019;70:53-56. [DOI: 10.1007/s00105-018-4333-0] [Reference Citation Analysis]
87 McGrath ER, Doughty CT, Amato AA. Autoimmune Myopathies: Updates on Evaluation and Treatment. Neurotherapeutics 2018;15:976-94. [PMID: 30341597 DOI: 10.1007/s13311-018-00676-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
88 de Souza JM, Hoff LS, Shinjo SK. Intravenous human immunoglobulin and/or methylprednisolone pulse therapies as a possible treat-to-target strategy in immune-mediated necrotizing myopathies. Rheumatol Int 2019;39:1201-12. [PMID: 30778655 DOI: 10.1007/s00296-019-04254-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
89 Dell SD, Schneider R, Yeung RS. Pulmonary Involvement in the Systemic Inflammatory Diseases of Childhood. Kendig's Disorders of the Respiratory Tract in Children 2019. [DOI: 10.1016/b978-0-323-44887-1.00058-4] [Reference Citation Analysis]
90 Fioravanti A, Tenti S. Intravenous Immunoglobulin Treatment in Rheumatic Diseases. Mosaic of Autoimmunity 2019. [DOI: 10.1016/b978-0-12-814307-0.00061-x] [Reference Citation Analysis]
91 Pelechas E, Kaltsonoudis E, Voulgari PV, Drosos AA. Inflammatory Myopathies. Illustrated Handbook of Rheumatic and Musculo-Skeletal Diseases 2019. [DOI: 10.1007/978-3-030-03664-5_9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 Lahouti AH, Christopher-stine L. Inflammatory Muscle Diseases. Clinical Immunology 2019. [DOI: 10.1016/b978-0-7020-6896-6.00056-9] [Reference Citation Analysis]
93 Yamada M, Nakashima K, Ito H, Aoshima M. Severe acute respiratory failure due to Sai-rei-to-induced lung injury successfully treated by multi-modal therapy including immunosuppressive therapy, plasma exchange, and intravenous immunoglobulin: A case report. Respiratory Medicine Case Reports 2019;28:100955. [DOI: 10.1016/j.rmcr.2019.100955] [Reference Citation Analysis]
94 Kohsaka H, Mimori T, Kanda T, Shimizu J, Sunada Y, Fujimoto M, Kawaguchi Y, Jinnin M, Muro Y, Ishihara S, Tomimitsu H, Ohta A, Sumida T. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Neurology & Clinical Neurosc 2019;7:3-21. [DOI: 10.1111/ncn3.12223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
95 McNeil M, Craig F, Meredith F. The use of subcutaneous immunoglobulins in the treatment of dermatomyositis. Clin Exp Dermatol 2019;44:e51-2. [PMID: 30506704 DOI: 10.1111/ced.13842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
96 Hallowell RW, Danoff SK. Treatment of Interstitial Lung Disease Associated With Myositis and the Anti-Synthetase Syndrome. Curr Treat Options in Rheum 2018;4:316-328. [DOI: 10.1007/s40674-018-0111-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
97 Moghadam-kia S, Aggarwal R, Oddis CV. Myositis in clinical practice—relevance of new antibodies. Best Practice & Research Clinical Rheumatology 2018;32:887-901. [DOI: 10.1016/j.berh.2019.03.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
98 Barsotti S, Lundberg IE. Current Treatment for Myositis. Curr Treatm Opt Rheumatol 2018;4:299-315. [PMID: 30613465 DOI: 10.1007/s40674-018-0106-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
99 Clapp ADM. Intravenous immunoglobulin is a treatment option for refractory dermatomyositis in adult patients. Clin Res Pract 2018;4. [DOI: 10.22237/crp/1536278640] [Reference Citation Analysis]
100 Berk-Krauss J, Lee K, Lo Sicco KI, Liebman TN. Eczematous reaction to IVIG for the treatment of dermatomyositis. Int J Womens Dermatol 2018;4:170-3. [PMID: 30175220 DOI: 10.1016/j.ijwd.2018.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
101 Schmidt J. Current Classification and Management of Inflammatory Myopathies. J Neuromuscul Dis 2018;5:109-29. [PMID: 29865091 DOI: 10.3233/JND-180308] [Cited by in Crossref: 117] [Cited by in F6Publishing: 124] [Article Influence: 23.4] [Reference Citation Analysis]
102 Navarro-triviño F, Pérez-lópez I, Ruíz-villaverde R. Dermatology and Immunoglobulin Therapy: Who to Treat and How to Administer Immunoglobulins. Actas Dermo-Sifiliográficas (English Edition) 2018;109:323-330. [DOI: 10.1016/j.adengl.2018.03.010] [Reference Citation Analysis]
103 Selva-O'Callaghan A, Alvarado-Cardenas M, Pinal-Fernández I, Trallero-Araguás E, Milisenda JC, Martínez MÁ, Marín A, Labrador-Horrillo M, Juárez C, Grau-Junyent JM. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol 2018;14:215-24. [PMID: 29473763 DOI: 10.1080/1744666X.2018.1440206] [Cited by in Crossref: 69] [Cited by in F6Publishing: 54] [Article Influence: 13.8] [Reference Citation Analysis]
104 Chansky PB, Mittal L, Sunderkötter C, Werth VP. Dermatomyositis. Pigmented Ethnic Skin and Imported Dermatoses 2018. [DOI: 10.1007/978-3-319-69422-1_31] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
105 Hoffmann JHO, Enk AH. Use of Intravenous Immunoglobulin in Dermatology. Antibody Therapy 2018. [DOI: 10.1007/978-3-319-68038-5_9] [Reference Citation Analysis]
106 Imbach P. Manual of Intravenous and Subcutaneous IgG Indications in Autoimmune Diseases. Antibody Therapy 2018. [DOI: 10.1007/978-3-319-68038-5_4] [Reference Citation Analysis]
107 Khadilkar SV, Yadav RS, Patel BA. Idiopathic Inflammatory Myopathies. Neuromuscular Disorders 2018. [DOI: 10.1007/978-981-10-5361-0_11] [Reference Citation Analysis]
108 Cathcart-rake E, Dronca R, Loprinzi CL. Neuromuscular Disease and Spinal Cord Compression. The MASCC Textbook of Cancer Supportive Care and Survivorship 2018. [DOI: 10.1007/978-3-319-90990-5_34] [Reference Citation Analysis]
109 Miossi R. Tratamento medicamentoso em miopatias autoimunes sistêmicas. Rev Paul Reumatol 2017. [DOI: 10.46833/reumatologiasp.2017.16.4.17-20] [Reference Citation Analysis]
110 Hoffmann JHO, Enk AH. High-dose intravenous immunoglobulins for the treatment of dermatological autoimmune diseases. J Dtsch Dermatol Ges 2017;15:1211-26. [PMID: 29228499 DOI: 10.1111/ddg.13389] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
111 Yuen E. Unusual Cause of Fever in a 35-Year-Old Man. Hong Kong Journal of Emergency Medicine 2001;8:34-7. [DOI: 10.1177/102490790100800105] [Reference Citation Analysis]
112 Hoffmann JH, Enk AH. Hochdosierte intravenöse Immunglobuline bei dermatologischen Autoimmunerkrankungen. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2017;15:1211-27. [DOI: 10.1111/ddg.13389_g] [Reference Citation Analysis]
113 Parker MJ, Chinoy H. The Treatment Approach of Idiopathic Inflammatory Myopathies. EMJ 2017. [DOI: 10.33590/emj/10314259] [Reference Citation Analysis]
114 Walker UA, Clements PJ, Allanore Y, Distler O, Oddis CV, Khanna D, Furst DE. Muscle involvement in systemic sclerosis: points to consider in clinical trials. Rheumatology (Oxford) 2017;56:v38-44. [PMID: 28992167 DOI: 10.1093/rheumatology/kex196] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
115 Miller JB, Paik JJ. Overlap Syndromes in Inflammatory Myopathies. Curr Treat Options in Rheum 2017;3:289-98. [DOI: 10.1007/s40674-017-0074-y] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
116 Sticherling M. Biomarker gewinnen an Bedeutung. Dtsch Dermatolog 2017;65:758-765. [DOI: 10.1007/s15011-017-1616-1] [Reference Citation Analysis]
117 Nayak R. Practical approach to the patient with acute neuromuscular weakness. World J Clin Cases 2017; 5(7): 270-279 [PMID: 28798922 DOI: 10.12998/wjcc.v5.i7.270] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
118 Inmunoglobulina endovenosa en enfermedades neuromusculares. Actualización de la guía para su utilización. Neurología Argentina 2017;9:140-155. [DOI: 10.1016/j.neuarg.2017.05.003] [Reference Citation Analysis]
119 Anyanwu CO, Chansky PB, Feng R, Carr K, Okawa J, Werth VP. The systemic management of cutaneous dermatomyositis: Results of a stepwise strategy. Int J Womens Dermatol 2017;3:189-94. [PMID: 29234712 DOI: 10.1016/j.ijwd.2017.05.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
120 Witte T. [Therapeutic administration of immunoglobulins]. Z Rheumatol 2016;75:956-63. [PMID: 27796482 DOI: 10.1007/s00393-016-0217-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
121 Zhou H, Olsen H, So E, Mérigeon E, Rybin D, Owens J, LaRosa G, Block DS, Strome SE, Zhang X. A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b. Blood Adv 2017;1:504-15. [PMID: 29296968 DOI: 10.1182/bloodadvances.2016001917] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
122 Moghadam-Kia S, Oddis CV, Aggarwal R. Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics. Clin Rev Allergy Immunol 2017;52:81-7. [PMID: 26767526 DOI: 10.1007/s12016-016-8530-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
123 Cavazzana I, Fredi M, Selmi C, Tincani A, Franceschini F. The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies. Clin Rev Allergy Immunol 2017;52:88-98. [PMID: 26514357 DOI: 10.1007/s12016-015-8517-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
124 Sticherling M. Malignomrisiko erfordert enges Monitoring. hautnah dermatologie 2017;33:34-39. [DOI: 10.1007/s15012-017-2308-y] [Reference Citation Analysis]
125 Mehta S, Himes RW. Effect of Systemic Illness, Medication, Radiation, and Infection on the Esophagus. Esophageal and Gastric Disorders in Infancy and Childhood 2017. [DOI: 10.1007/978-3-642-11202-7_63] [Reference Citation Analysis]
126 Mannering IK, Yu Y, Grando SA. Intravenous Immunoglobulin: Dermatologic Uses and Mechanisms of Action. Clinical and Basic Immunodermatology 2017. [DOI: 10.1007/978-3-319-29785-9_50] [Reference Citation Analysis]
127 Lünemann JD, Quast I, Dalakas MC. Efficacy of Intravenous Immunoglobulin in Neurological Diseases. Neurotherapeutics 2016;13:34-46. [PMID: 26400261 DOI: 10.1007/s13311-015-0391-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 6.9] [Reference Citation Analysis]
128 Needham M, Mastaglia FL. Immunotherapies for Immune-Mediated Myopathies: A Current Perspective. Neurotherapeutics 2016;13:132-46. [PMID: 26586486 DOI: 10.1007/s13311-015-0394-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
129 Kampylafka EI, Alexopoulos H, Dalakas MC, Tzioufas AG. Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity. Neurotherapeutics 2016;13:163-78. [PMID: 26510559 DOI: 10.1007/s13311-015-0393-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
130 Uzunhan Y, Freynet O, Hervier B, Guyot A, Miyara M, Nunes H. Les manifestations respiratoires au cours des myopathies inflammatoires idiopathiques. Méd Intensive Réa 2016. [DOI: 10.1007/s13546-016-1232-1] [Reference Citation Analysis]
131 Witt LJ, Curran JJ, Strek ME. The Diagnosis and Treatment of Antisynthetase Syndrome. Clin Pulm Med 2016;23:218-26. [PMID: 27594777 DOI: 10.1097/CPM.0000000000000171] [Cited by in Crossref: 100] [Cited by in F6Publishing: 107] [Article Influence: 14.3] [Reference Citation Analysis]
132 Nardin RA, Drislane FW. Neurologic Causes of Acute Respiratory Dysfunction. J Intensive Care Med 2000;15:29-47. [DOI: 10.1177/088506660001500103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
133 Kafaja S, Clements P. Management of Widespread Skin Thickening in Diffuse Systemic Sclerosis. Curr Treatm Opt Rheumatol 2016;2:49-60. [PMID: 27330933 DOI: 10.1007/s40674-016-0040-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
134 Malik A, Hayat G, Kalia JS, Guzman MA. Idiopathic Inflammatory Myopathies: Clinical Approach and Management. Front Neurol 2016;7:64. [PMID: 27242652 DOI: 10.3389/fneur.2016.00064] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 9.4] [Reference Citation Analysis]
135 Volc-Platzer B. [Dermatomyositis-update]. Hautarzt 2015;66:604-10. [PMID: 26219226 DOI: 10.1007/s00105-015-3659-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
136 Dalakas MC. Dermatomyositis. International Neurology 2016. [DOI: 10.1002/9781118777329.ch121] [Reference Citation Analysis]
137 Barahona Afonso AF, João CM. The Production Processes and Biological Effects of Intravenous Immunoglobulin. Biomolecules 2016;6:15. [PMID: 27005671 DOI: 10.3390/biom6010015] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 7.6] [Reference Citation Analysis]
138 Sunderkötter C, Nast A, Worm M, Dengler R, Dörner T, Ganter H, Hohlfeld R, Melms A, Melzer N, Rösler K, Schmidt J, Sinnreich M, Walter MC, Wanschitz J, Wiendl H. Leitlinie Dermatomyositis - Auszug aus der interdisziplinären S2k-Leitlinie zu Myositissyndromen der deutschen Gesellschaft für Neurologie. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2016;14:e1-e20. [DOI: 10.1111/ddg.12909_g] [Reference Citation Analysis]
139 Živković S. Intravenous immunoglobulin in the treatment of neurologic disorders. Acta Neurol Scand 2016;133:84-96. [PMID: 25997034 DOI: 10.1111/ane.12444] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
140 Dourmishev LA, Guleva DV, Miteva LG. Intravenous Immunoglobulins: Mode of Action and Indications in Autoimmune and Inflammatory Dermatoses. Int J Inflam 2016;2016:3523057. [PMID: 26885437 DOI: 10.1155/2016/3523057] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
141 Dalakas MC. The Spectrum of Inflammatory Myopathies: Dermatomyositis, Polymyositis, Necrotizing Myositis, and Inclusion-Body Myositis. Acquired Neuromuscular Disorders 2016. [DOI: 10.1007/978-3-319-29514-5_6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
142 Lehman HK, Ballow M. Immunoglobulin Therapy. Pediatric Allergy: Principles and Practice 2016. [DOI: 10.1016/b978-0-323-29875-9.00015-x] [Reference Citation Analysis]
143 Murphy GM, Ralph N. Photoprotection, Photoimmunology and Autoimmune Diseases. Principles and Practice of Photoprotection 2016. [DOI: 10.1007/978-3-319-29382-0_5] [Reference Citation Analysis]
144 Cafardi JM, Sami N. Intravenous Immune Globulin in Amyopathic Dermatomyositis - Report of Two Cases and Review of the Literature. Open Rheumatol J 2015;9:77-81. [PMID: 26668670 DOI: 10.2174/1874312901409010077] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
145 Postolova A, Chen JK, Chung L. Corticosteroids in Myositis and Scleroderma. Rheum Dis Clin North Am 2016;42:103-18, ix. [PMID: 26611554 DOI: 10.1016/j.rdc.2015.08.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
146 Bembeeva RT, Zavadenko NN. [Intravenous immunoglobulin in treatment of autoimmune neurological diseases in children]. Zh Nevrol Psikhiatr Im S S Korsakova 2015;115:83-93. [PMID: 26356621 DOI: 10.17116/jnevro20151156183-93] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
147 Papo T. Inmunoglobulinas polivalentes por vía intravenosa. EMC - Tratado de Medicina 2015;19:1-7. [DOI: 10.1016/s1636-5410(15)72805-9] [Reference Citation Analysis]
148 Papo T. Immunoglobuline polivalenti per via endovenosa. EMC - AKOS - Trattato di Medicina 2015;17:1-7. [DOI: 10.1016/s1634-7358(15)72345-4] [Reference Citation Analysis]
149 Moghadam-Kia S, Aggarwal R, Oddis CV. Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert Rev Clin Immunol 2015;11:1265-75. [PMID: 26313852 DOI: 10.1586/1744666X.2015.1082908] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
150 De Paepe B, Zschüntzsch J. Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies. Int J Mol Sci 2015;16:18683-713. [PMID: 26270565 DOI: 10.3390/ijms160818683] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
151 Hornung T, Wenzel J. Innate immune-response mechanisms in dermatomyositis: an update on pathogenesis, diagnosis and treatment. Drugs 2014;74:981-98. [PMID: 24939511 DOI: 10.1007/s40265-014-0240-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
152 Dimachkie MM, Barohn RJ, Amato AA. Idiopathic inflammatory myopathies. Neurol Clin 2014;32:595-628, vii. [PMID: 25037081 DOI: 10.1016/j.ncl.2014.04.007] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 7.1] [Reference Citation Analysis]
153 Allenbach Y, Benveniste O. Polimiositis, dermatomiositis y otras miopatías inflamatorias idiopáticas. EMC - Aparato Locomotor 2015;48:1-11. [DOI: 10.1016/s1286-935x(15)70083-3] [Reference Citation Analysis]
154 van de Vlekkert J, Hoogendijk JE, de Visser M. Long-term follow-up of 62 patients with myositis. J Neurol 2014;261:992-8. [PMID: 24658663 DOI: 10.1007/s00415-014-7313-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
155 Ohkubo H, Fukumitsu K, Niimi A. Refractory Interstitial Lung Disease of Dermatomyositis: A Proposal for a Prospective Trial for Establishing Evidence. Intern Med 2015;54:2099-2100. [DOI: 10.2169/internalmedicine.54.5035] [Reference Citation Analysis]
156 Miller FW. Management of inflammatory muscle disease. Rheumatology 2015. [DOI: 10.1016/b978-0-323-09138-1.00150-9] [Reference Citation Analysis]
157 Badem H, Yildirim ME, Badem S, Balçık ÖŞ. An Unusual Paraneoplastic Syndrome of Synchronous Bladder Tumor and Prostate Cancer: Polymyositis. OJU 2015;05:179-181. [DOI: 10.4236/oju.2015.510028] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
158 Troy L, Hamor P, Bleasel J, Corte T. Two simultaneous autoimmune processes in a patient presenting with respiratory insufficiency. Respirol Case Rep 2014;2:21-3. [PMID: 25473554 DOI: 10.1002/rcr2.36] [Reference Citation Analysis]
159 Breithaupt M, Schmidt J. Diagnostik und Therapie von Myositiden. NeuroTransmitter 2014;25:46-56. [DOI: 10.1007/s15016-014-0570-3] [Reference Citation Analysis]
160 Ibrahim F, Choy E, Gordon P, Doré CJ, Hakim A, Kitas G, Isenberg D, Griffiths B, Lecky B, Chakravarty K, Winer J, Danko K, Cooper RG, White-Alao B, Scott DL. Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. Rheumatology (Oxford) 2015;54:1050-5. [PMID: 25433040 DOI: 10.1093/rheumatology/keu442] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
161 Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases. Rheumatology (Oxford). 2015;54:383-391. [PMID: 25406359 DOI: 10.1093/rheumatology/keu429] [Cited by in Crossref: 33] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
162 Iaccarino L, Bartoloni E, Gerli R, Alunno A, Barsotti S, Cafaro G, Gatto M, Talarico R, Tripoli A, Zen M, Neri R, Doria A. Drugs in induction and treatment of idiopathic inflammatory myopathies. Auto Immun Highlights 2014;5:95-100. [PMID: 26000161 DOI: 10.1007/s13317-014-0065-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
163 Selva-O'Callaghan A, Ramos Casals M, Grau Junyent JM. [Biologic therapy in idiopathic inflammatory myopathy]. Med Clin (Barc) 2014;143:275-80. [PMID: 24393419 DOI: 10.1016/j.medcli.2013.11.009] [Reference Citation Analysis]
164 Işık M, Bilgen Ş, Doğan İ, Kılıç L. Inflammatory myopathies: One-center experience. Eur J Rheumatol 2014;1:96-100. [PMID: 27708887 DOI: 10.5152/eurjrheumatol.2014.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
165 Vleugels RA, Fiorentino DF, Callen JP. Dermatomyositis. Evidence-Based Dermatology 2014. [DOI: 10.1002/9781118357606.ch63] [Reference Citation Analysis]
166 Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC, Oddis CV; RIM Study Group. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014;66:740-9. [PMID: 24574235 DOI: 10.1002/art.38270] [Cited by in Crossref: 174] [Cited by in F6Publishing: 181] [Article Influence: 19.3] [Reference Citation Analysis]
167 Dalakas MC. Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations. J Clin Immunol 2014;34 Suppl 1:S120-6. [PMID: 24722854 DOI: 10.1007/s10875-014-0024-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
168 Davies R, Choy E. Idiopathic inflammatory myopathy. Medicine 2014;42:174-179. [DOI: 10.1016/j.mpmed.2013.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
169 Alexanderson H, Del Grande M, Bingham CO 3rd, Orbai AM, Sarver C, Clegg-Smith K, Lundberg IE, Song YW, Christopher-Stine L. Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 Myositis Special Interest Group. J Rheumatol 2014;41:581-92. [PMID: 24429182 DOI: 10.3899/jrheum.131247] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
170 Nakamura H, Fujikawa K, Kawakami A, Tamai M, Yamasaki S, Ida H, Eguchi K. Long-term efficacy of intravenously administered immunoglobulin in a case of polymyositis with limited application of steroid therapy. Modern Rheumatology 2014;20:496-9. [DOI: 10.3109/s10165-010-0298-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
171 Ralph JW, Aminoff MJ. Neuromuscular Complications of General Medical Disorders. Aminoff's Neurology and General Medicine 2014. [DOI: 10.1016/b978-0-12-407710-2.00059-x] [Reference Citation Analysis]
172 Goyal N, Chad DA. Inflammatory Myopathies. Neuromuscular Disorders in Clinical Practice 2014. [DOI: 10.1007/978-1-4614-6567-6_65] [Reference Citation Analysis]
173 Bansal VK, Meriggioli MN. Immunotherapy in the Treatment of Autoimmune Neuromuscular Diseases. Neuromuscular Disorders in Clinical Practice 2014. [DOI: 10.1007/978-1-4614-6567-6_17] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
174 Hahn BH, King JK. Treatment of Autoimmune Disease. The Autoimmune Diseases 2014. [DOI: 10.1016/b978-0-12-384929-8.00080-0] [Reference Citation Analysis]
175 Horneff G, Wahn V. Autoimmunerkrankungen. Therapie der Krankheiten im Kindes- und Jugendalter 2014. [DOI: 10.1007/978-3-642-41814-3_46] [Reference Citation Analysis]
176 Korinthenberg R, Müller-felber W. Neuromuskuläre Erkrankungen. Neuropädiatrie 2014. [DOI: 10.1016/b978-3-437-23076-9.00015-2] [Reference Citation Analysis]
177 Adams TL, Marchiori DM. Arthritides. Clinical Imaging 2014. [DOI: 10.1016/b978-0-323-08495-6.00009-9] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
178 Dalmau J, Rosenfeld MR. Paraneoplastic Neurologic Syndromes. Abeloff's Clinical Oncology 2014. [DOI: 10.1016/b978-1-4557-2865-7.00039-4] [Reference Citation Analysis]
179 Simon NG, Ayer G, Lomen-Hoerth C. Is IVIg therapy warranted in progressive lower motor neuron syndromes without conduction block? Neurology. 2013;81:2116-2120. [PMID: 24212395 DOI: 10.1212/01.wnl.0000437301.28441.7e] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
180 Rider LG, Katz JD, Jones OY. Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2013;39:877-904. [PMID: 24182859 DOI: 10.1016/j.rdc.2013.06.001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 6.4] [Reference Citation Analysis]
181 Zuber MA, Kouba M, Rudolph SE, Weller M, Hrdlicka P. [Severe dysphagia and erythrodermia in a 59-year-old man]. Internist (Berl) 2013;54:359-65. [PMID: 23404266 DOI: 10.1007/s00108-012-3225-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
182 Femia AN, Vleugels RA, Callen JP. Cutaneous dermatomyositis: an updated review of treatment options and internal associations. Am J Clin Dermatol 2013;14:291-313. [PMID: 23754636 DOI: 10.1007/s40257-013-0028-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
183 Izumi Y, Miyashita T, Kitajima T, Yoshimura S, Takeoka A, Eguchi K, Motomura M, Kawakami A, Migita K. Two cases of refractory polymyositis accompanied with steroid myopathy. Mod Rheumatol 2013. [DOI: 10.1007/s10165-013-0858-3] [Reference Citation Analysis]
184 Keck A, Walker U. Therapie der Myositiden. Z Rheumatol 2013;72:227-35. [DOI: 10.1007/s00393-012-1080-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
185 Laxer RM, Benseler SM. Pediatric Systemic Lupus Erythematosus, Dermatomyositis, Scleroderma, and Vasculitis. Kelley's Textbook of Rheumatology 2013. [DOI: 10.1016/b978-1-4377-1738-9.00108-0] [Reference Citation Analysis]
186 Mouthon L. Traitements immunomodulateurs et complications spécifiques. Maladies rares en médecine d’urgence 2013. [DOI: 10.1007/978-2-8178-0350-0_4] [Reference Citation Analysis]
187 Ballow MC. Immunoglobulin therapy. Clinical Immunology 2013. [DOI: 10.1016/b978-0-7234-3691-1.00098-2] [Reference Citation Analysis]
188 Nagaraju K, Lundberg IE. Inflammatory Diseases of Muscle and Other Myopathies. Kelley's Textbook of Rheumatology 2013. [DOI: 10.1016/b978-1-4377-1738-9.00085-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
189 Aggarwal R, Oddis CV. Perioperative Management of the Patient with Idiopathic Inflammatory Myopathy. Perioperative Management of Patients with Rheumatic Disease 2013. [DOI: 10.1007/978-1-4614-2203-7_16] [Reference Citation Analysis]
190 Goerge T, Luger TA. Intravenous immunoglobulin therapy. Comprehensive Dermatologic Drug Therapy 2013. [DOI: 10.1016/b978-1-4377-2003-7.00032-7] [Reference Citation Analysis]
191 Christopher-stine L, Khan S. Inflammatory muscle diseases. Clinical Immunology 2013. [DOI: 10.1016/b978-0-7234-3691-1.00069-6] [Reference Citation Analysis]
192 Krishnamurthy A, Lee DH, Chan A. Cutaneous Findings of Collagen Vascular Disease and Related Emergent Complications. Buka's Emergencies in Dermatology 2013. [DOI: 10.1007/978-1-4614-5031-3_11] [Reference Citation Analysis]
193 Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2012;12:CD002277. [PMID: 23235588 DOI: 10.1002/14651858.CD002277.pub4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 52] [Article Influence: 3.5] [Reference Citation Analysis]
194 Dimachkie MM, Barohn RJ. Idiopathic inflammatory myopathies. Semin Neurol 2012;32:227-36. [PMID: 23117947 DOI: 10.1055/s-0032-1329201] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
195 Hunter K, Lyon MG. Evaluation and management of polymyositis. Indian J Dermatol. 2012;57:371-374. [PMID: 23112357 DOI: 10.4103/0019-5154.100479] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
196 Braunstein I, Werth VP. Update on management of connective tissue panniculitides. Dermatol Ther 2012;25:173-82. [PMID: 22741936 DOI: 10.1111/j.1529-8019.2012.01489.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
197 Gazeley DJ, Cronin ME. Diagnosis and treatment of the idiopathic inflammatory myopathies. Ther Adv Musculoskelet Dis 2011;3:315-24. [PMID: 22870489 DOI: 10.1177/1759720X11415306] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
198 Martin N, Li CK, Wedderburn LR. Juvenile dermatomyositis: new insights and new treatment strategies. Ther Adv Musculoskelet Dis 2012;4:41-50. [PMID: 22870494 DOI: 10.1177/1759720X11424460] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
199 Castro C, Gourley M. Diagnosis and treatment of inflammatory myopathy: issues and management. Ther Adv Musculoskelet Dis 2012;4:111-20. [PMID: 22870499 DOI: 10.1177/1759720X11425092] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
200 Shahani L. Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin. BMJ Case Rep 2012;2012:bcr2012006629. [PMID: 22907859 DOI: 10.1136/bcr-2012-006629] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
201 Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2012;:CD003643. [PMID: 22895935 DOI: 10.1002/14651858.CD003643.pub4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 61] [Article Influence: 3.5] [Reference Citation Analysis]
202 Crum BA, Rubin DI, Dimberg EL, Goodman BP. Neuromuscular Disorders. Neurology 2012. [DOI: 10.1007/978-0-387-88555-1_9] [Reference Citation Analysis]
203 Kapitel E1 Literaturverzeichnis zu Peter, Pichler, Müller-Ladner (Hrsg.): Klinische Immunologie. Klinische Immunologie 2012. [DOI: 10.1016/b978-3-437-23256-5.16001-1] [Reference Citation Analysis]
204 Rosenfeld MR, Dalmau J. Cancer and the Nervous System. Neurology in Clinical Practice 2012. [DOI: 10.1016/b978-1-4377-0434-1.00074-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
205 Amato AA, Kissel JT. Inflammatory Myopathies. Swaiman's Pediatric Neurology 2012. [DOI: 10.1016/b978-1-4377-0435-8.00090-1] [Reference Citation Analysis]
206 Jolles S, Stein MR, Longhurst HJ, Borte M, Ritchie B, Sturzenegger MH, Berger M. New Frontiers in Subcutaneous Immunoglobulin Treatment. Biol Ther 2011;1:3. [PMID: 24392293 DOI: 10.1007/s13554-011-0009-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
207 Stangel M. New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins. Ther Adv Neurol Disord 2008;1:52-61. [PMID: 21180569 DOI: 10.1177/1756285608095747] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
208 Baleva M, Nikolov K. The role of intravenous immunoglobulin preparations in the treatment of systemic sclerosis. Int J Rheumatol 2011;2011:829751. [PMID: 22121376 DOI: 10.1155/2011/829751] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
209 Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y; GB-0998 Study Group. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol 2012;22:382-93. [PMID: 21971943 DOI: 10.1007/s10165-011-0534-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 0.3] [Reference Citation Analysis]
210 Robinson AB, Reed AM. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol 2011;7:664-75. [PMID: 21947177 DOI: 10.1038/nrrheum.2011.139] [Cited by in Crossref: 78] [Cited by in F6Publishing: 83] [Article Influence: 6.5] [Reference Citation Analysis]
211 Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, van Schaik IN, Scolding N, Sørensen PS, Udd B. Intravenous Immunoglobulin in the Treatment of Neurological Diseases. European Handbook of Neurological Management 2011. [DOI: 10.1002/9781444346268.ch9] [Reference Citation Analysis]
212 Quick A, Tandan R. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease. Curr Rheumatol Rep 2011;13:192-8. [PMID: 21503696 DOI: 10.1007/s11926-011-0171-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
213 Distad BJ, Amato AA, Weiss MD. Inflammatory myopathies. Curr Treat Options Neurol 2011;13:119-30. [PMID: 21222061 DOI: 10.1007/s11940-010-0111-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
214 Dalakas MC. Therapeutic advances and future prospects in immune-mediated inflammatory myopathies. Ther Adv Neurol Disord 2008;1:157-66. [PMID: 21180574 DOI: 10.1177/1756285608097463] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
215 Waterhouse C. Promoting the safe administration of immunoglobulins in neuroscience. British Journal of Neuroscience Nursing 2011;7:529-535. [DOI: 10.12968/bjnn.2011.7.3.529] [Reference Citation Analysis]
216 Chakroun A, Guigay J, Lusinchi A, Marandas P, Janot F, Hartl D. Dermatomyosite paranéoplasique et carcinome nasopharyngé : diagnostic, traitement et pronostic. Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale 2011;128:148-152. [DOI: 10.1016/j.aforl.2010.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
217 Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol. 2011;7:349-359. [PMID: 21556030 DOI: 10.1038/nrrheum.2011.61] [Cited by in Crossref: 96] [Cited by in F6Publishing: 103] [Article Influence: 8.0] [Reference Citation Analysis]
218 Ikeda T, Kimura E, Hirano T, Uchino M. The association between dermatomyositis and papillary thyroid cancer: a case report. Rheumatol Int 2012;32:959-61. [PMID: 21243494 DOI: 10.1007/s00296-010-1763-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
219 Dalakas MC. Treatment and Management of Autoimmune Myopathies. Neuromuscular Disorders: Treatment and Management 2011. [DOI: 10.1016/b978-1-4377-0372-6.00021-9] [Reference Citation Analysis]
220 Cherin P. Miositi. EMC - AKOS - Trattato di Medicina 2011;13:1-11. [DOI: 10.1016/s1634-7358(11)70673-8] [Reference Citation Analysis]
221 Miller FW. Management of inflammatory muscle disease. Rheumatology 2011. [DOI: 10.1016/b978-0-323-06551-1.00146-9] [Reference Citation Analysis]
222 Ruzicka T, Wolff H, Thomas P, Prinz J. Update und neue technische Entwicklungen. Fortschritte der praktischen Dermatologie und Venerologie 2011. [DOI: 10.1007/978-3-642-10358-2_7] [Reference Citation Analysis]
223 Benveniste O. Médecine interne et réanimation — Polymyosites et dermatomyosites. Réanimation 2011;20:313-319. [DOI: 10.1007/s13546-010-0109-y] [Reference Citation Analysis]
224 Lioger B, Lavigne C, Machet L. Dermatomiositis. EMC - Dermatología 2011;45:1-12. [DOI: 10.1016/s1761-2896(11)71043-3] [Reference Citation Analysis]
225 Cherin P. Myosites. EMC - Traité de médecine AKOS 2011;6:1-11. [DOI: 10.1016/s1634-6939(11)49767-2] [Reference Citation Analysis]
226 Vleugels RA, Callen JP. Dermatomyositis. Autoimmune Diseases of the Skin 2011. [DOI: 10.1007/978-3-211-99225-8_11] [Reference Citation Analysis]
227 Tacik P, Zierz S. Entzündliche, endokrine und toxische Muskelerkrankungen. Klinische Neurologie 2011. [DOI: 10.1007/978-3-642-16920-5_11] [Reference Citation Analysis]
228 Gordon P, Lundberg IE. Myositis: When Weakness Can Kill. Autoimmune Diseases 2011. [DOI: 10.1007/978-0-85729-358-9_12] [Reference Citation Analysis]
229 Elovaara I, Hietaharju A. Can we face the challenge of expanding use of intravenous immunoglobulin in neurology? Acta Neurol Scand 2010;122:309-15. [PMID: 20085560 DOI: 10.1111/j.1600-0404.2009.01317.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
230 Cherin P, Grivel T. [Immunoglobulins: multiple potential therapeutic proteins for use in autoimmune disorders]. Rev Med Interne 2010;31:H12-6. [PMID: 20965369 DOI: 10.1016/S0248-8663(10)70008-4] [Reference Citation Analysis]
231 Nakamura H, Fujikawa K, Kawakami A, Tamai M, Yamasaki S, Ida H, Eguchi K. Long-term efficacy of intravenously administered immunoglobulin in a case of polymyositis with limited application of steroid therapy. Mod Rheumatol 2010;20:496-499. [DOI: 10.1007/s10165-010-0298-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
232 Tournadre A, Dubost J, Soubrier M. Comment traiter une myopathie inflammatoire de l’adulte ? Revue du Rhumatisme 2010;77:333-337. [DOI: 10.1016/j.rhum.2010.01.013] [Reference Citation Analysis]
233 Kivity S, Katz U, Daniel N, Nussinovitch U, Papageorgiou N, Shoenfeld Y. Evidence for the use of intravenous immunoglobulins--a review of the literature. Clin Rev Allergy Immunol 2010;38:201-69. [PMID: 19590986 DOI: 10.1007/s12016-009-8155-9] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 4.8] [Reference Citation Analysis]
234 Dalakas MC. Dermatomyositis. International Neurology 2010. [DOI: 10.1002/9781444317008.ch122] [Reference Citation Analysis]
235 Breathnach SM, Smith CH, Chalmers RJG, Hay RJ. Systemic Therapy. Rook's Textbook of Dermatology 2010. [DOI: 10.1002/9781444317633.ch74] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
236 Haroon M, Devlin J. Rituximab as a first-line agent for the treatment of dermatomyositis. Rheumatol Int 2012;32:1783-4. [PMID: 20340018 DOI: 10.1007/s00296-010-1458-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
237 Fernandez-Cruz E, Kaveri SV, Peter HH, Durandy A, Cantoni N, Quinti I, Sorensen R, Bussel JB, Danieli MG, Winkelmann A, Bayry J, Käsermann F, Späth P, Helbert M, Salama A, van Schaik IN, Yuki N. 6th International Immunoglobulin Symposium: poster presentations. Clin Exp Immunol 2009;158 Suppl 1:60-7. [PMID: 19883425 DOI: 10.1111/j.1365-2249.2009.04028.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
238 Hughes RA, Dalakas MC, Cornblath DR, Latov N, Weksler ME, Relkin N. Clinical applications of intravenous immunoglobulins in neurology. Clin Exp Immunol 2009;158 Suppl 1:34-42. [PMID: 19883422 DOI: 10.1111/j.1365-2249.2009.04025.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 4.0] [Reference Citation Analysis]
239 Ebert EC. Review article: the gastrointestinal complications of myositis. Aliment Pharmacol Ther 2010;31:359-65. [PMID: 19886949 DOI: 10.1111/j.1365-2036.2009.04190.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 4.8] [Reference Citation Analysis]
240 Choy E, Gordon P. Idiopathic inflammatory myopathy. Medicine 2010;38:116-120. [DOI: 10.1016/j.mpmed.2009.10.015] [Reference Citation Analysis]
241 Description of muscle disease – specific diseases. Disorders of Voluntary Muscle 2010. [DOI: 10.1017/cbo9780511674747.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
242 Hasegawa M, Sato S. Connective Tissue Diseases. Therapy of Skin Diseases 2010. [DOI: 10.1007/978-3-540-78814-0_37] [Reference Citation Analysis]
243 Miscellaneous Neurological Disorders. Clinical Neurology 2010. [DOI: 10.1016/b978-0-7295-3935-7.10014-8] [Reference Citation Analysis]
244 Lioger B, Lavigne C, Machet L. Dermatomyosite. EMC - Dermatologie 2010;5:1-12. [DOI: 10.1016/s0246-0319(10)54161-x] [Reference Citation Analysis]
245 Wahezi DM, Ilowite NT. Management of the Connective Tissue Diseases of Childhood. Targeted Treatment of the Rheumatic Diseases 2010. [DOI: 10.1016/b978-1-4160-9993-2.00019-9] [Reference Citation Analysis]
246 Dastmalchi M, Alexandersson H. Targeted Treatment of the Idiopathic Inflammatory Myopathies. Targeted Treatment of the Rheumatic Diseases 2010. [DOI: 10.1016/b978-1-4160-9993-2.00014-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
247 Hirose K, Kubo Y, Noda T, Arase S, Makino H, Endo A, Utsunomiya M. Two Cases of Dermatomyositis with Dysphasia Successfully Treated with IVIG. Nishinihon J Dermatol 2010;72:344-348. [DOI: 10.2336/nishinihonhifu.72.344] [Reference Citation Analysis]
248 Rosenfeld MR, Dalmau J. Paraneoplastic Disorders. Blue Books of Neurology 2010. [DOI: 10.1016/b978-0-7506-7516-1.00018-9] [Reference Citation Analysis]
249 Shimizu J. 7. Polymyositis (PM) and Dermatomyositis (DM). J Jpn Soc Intern Med 2010;99:1795-1802. [DOI: 10.2169/naika.99.1795] [Reference Citation Analysis]
250 Lundberg IE, Munters LA. Inflammatory Myopathies. Muscle Pain: Diagnosis and Treatment 2010. [DOI: 10.1007/978-3-642-05468-6_8] [Reference Citation Analysis]
251 Dronca RS, Loprinzi CL, Lachance DH. Neuromuscular Disease and Spinal Cord Compression. The MASCC Textbook of Cancer Supportive Care and Survivorship 2010. [DOI: 10.1007/978-1-4419-1225-1_32] [Reference Citation Analysis]
252 Duró Pujol JC. Miopatías inflamatorias idiopáticas. Reumatología Clínica 2010. [DOI: 10.1016/b978-84-8086-645-3.50015-9] [Reference Citation Analysis]
253 Ballow M, Lehman HK. Intravenous Immune Serum Globulin (IVIG) Therapy in Patients with Antibody Immune Deficiency. Pediatric Allergy: Principles and Practice 2010. [DOI: 10.1016/b978-1-4377-0271-2.00017-1] [Reference Citation Analysis]
254 Levy DM, Bingham CA, Kahn PJ, Eichenfield AH, Imundo LF. Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids. J Pediatr 2010;156:302-7. [PMID: 19846111 DOI: 10.1016/j.jpeds.2009.09.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
255 Mileti LM, Strek ME, Niewold TB, Curran JJ, Sweiss NJ. Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience. J Clin Rheumatol 2009;15:254-5. [PMID: 19590436 DOI: 10.1097/RHU.0b013e3181b0e910] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
256 Cook IJ. Oropharyngeal dysphagia. Gastroenterol Clin North Am 2009;38:411-31. [PMID: 19699405 DOI: 10.1016/j.gtc.2009.06.003] [Cited by in Crossref: 103] [Cited by in F6Publishing: 100] [Article Influence: 7.4] [Reference Citation Analysis]
257 Rahim KF, Dawe RS. Dermatomyositis presenting with symptomatic dermographism and raised troponin T: a case report. J Med Case Rep 2009;3:7319. [PMID: 19830184 DOI: 10.4076/1752-1947-3-7319] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
258 Sánchez-Ramón S, Ravell JC, de la Torre I, Montoro M, Rodríguez-Mahou M, Carreño-Pérez L, Fernández-Cruz E, López-Longo FJ. Long-term remission of severe refractory dermatopolymyositis with a weekly-scheme of immunoglobulin followed by rituximab therapy. Rheumatol Int 2010;30:817-9. [PMID: 19536548 DOI: 10.1007/s00296-009-1000-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
259 Suzuki Y, Hayakawa H, Miwa S, Shirai M, Fujii M, Gemma H, Suda T, Chida K. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009;187:201-206. [PMID: 19387736 DOI: 10.1007/s00408-009-9146-6] [Cited by in Crossref: 92] [Cited by in F6Publishing: 79] [Article Influence: 6.6] [Reference Citation Analysis]
260 Castelo-Soccio L, Van Voorhees AS. Long-term efficacy of biologics in dermatology. Dermatol Ther 2009;22:22-33. [PMID: 19222514 DOI: 10.1111/j.1529-8019.2008.01213.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
261 Wiendl H. Idiopathic inflammatory myopathies: current and future therapeutic options. Neurotherapeutics 2008;5:548-57. [PMID: 19019306 DOI: 10.1016/j.nurt.2008.08.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
262 Korinthenberg R. Neuromuskuläre Erkrankungen. Neurologische Therapie im Kindesalter 2009. [DOI: 10.1016/b978-343723075-2.10017-2] [Reference Citation Analysis]
263 Pharmacologic Agents in the Treatment of DM. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_39] [Reference Citation Analysis]
264 Sacré K, Papo T. Immunoglobulines polyvalentes par voie intraveineuse. EMC - Traité de médecine AKOS 2009;4:1-7. [DOI: 10.1016/s1634-6939(09)49788-6] [Reference Citation Analysis]
265 Treatment of Cutaneous Manifestations and Complications of Dermatomyositis. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_40] [Reference Citation Analysis]
266 Odani T, Horita T. 5. High Dose Intravenous Immunoglobulin. J Jpn Soc Intern Med 2009;98:2512-2517. [DOI: 10.2169/naika.98.2512] [Reference Citation Analysis]
267 Swenson MR. Neuroimmunology. Atlas of Clinical Neurology 2009. [DOI: 10.1007/978-1-57340-359-7_13] [Reference Citation Analysis]
268 Pathogenesis of Dermatomyositis. Dermatomyositis 2009. [DOI: 10.1007/978-3-540-79313-7_37] [Reference Citation Analysis]
269 Bates T, Tarrant TK. Polymyositis and Dermatomyositis. Netter's Internal Medicine 2009. [DOI: 10.1016/b978-1-4160-4417-8.50163-7] [Reference Citation Analysis]
270 Dimartino SJ. Treatment. The Inflammatory Myopathies 2009. [DOI: 10.1007/978-1-60327-827-0_18] [Reference Citation Analysis]
271 Hartung HP. Advances in the understanding of the mechanism of action of IVIg. J Neurol. 2008;255 Suppl 3:3-6. [PMID: 18685919 DOI: 10.1007/s00415-008-3002-0] [Cited by in Crossref: 83] [Cited by in F6Publishing: 66] [Article Influence: 5.5] [Reference Citation Analysis]
272 Burmester GR, Buttgereit F. Dermatomyositis — Polymyositis (M 33). Interdisziplinäre klinische Rheumatologie. [DOI: 10.1007/978-3-540-34105-5_59] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
273 Callen JP. Immunomodulatory treatment for dermatomyositis. Curr Allergy Asthma Rep 2008;8:348-53. [PMID: 18606089 DOI: 10.1007/s11882-008-0055-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
274 Joshi D, Mahmood R, Williams P, Kitchen P. Dysphagia secondary to dermatomyositis treated successfully with intravenous immunoglobulin: a case report. Int Arch Med 2008;1:12. [PMID: 18651969 DOI: 10.1186/1755-7682-1-12] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
275 Rosenfeld MR, Dalmau J. Paraneoplastic Syndromes of the Nervous System. Cancer Neurology In Clinical Practice. [DOI: 10.1007/978-1-59745-412-4_15] [Reference Citation Analysis]
276 Kluge S, de Heer G, Nierhaus A, Kreymann G. [Immunoglobulins in primary antibody deficiency: should they also be used in sepsis and other indications?]. Internist (Berl) 2007;48:1297-302, 1304. [PMID: 17901939 DOI: 10.1007/s00108-007-1933-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
277 Horneff G, Wahn V. Autoimmunerkrankungen. Therapie der Krankheiten im Kindes- und Jugendalter. [DOI: 10.1007/978-3-540-71899-4_43] [Reference Citation Analysis]
278 Christopher-stine L, Plotz PH. Inflammatory muscle diseases. Clinical Immunology 2008. [DOI: 10.1016/b978-0-323-04404-2.10056-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
279 Serratrice J, Figarella-branger D, Schleinitz N, Pellissier J, Serratrice G. Myopathies inflammatoires. EMC - Neurologie 2008;5:1-23. [DOI: 10.1016/s0246-0378(08)29784-8] [Reference Citation Analysis]
280 Ralph JW, Aminoff MJ. Neuromuscular Complications of General Medical Disorders. Neurology and General Medicine 2008. [DOI: 10.1016/b978-044306707-5.50063-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
281 Serratrice J, Figarella-branger D, Schleinitz N, Pellissier J, Serratrice G. Miopatie infiammatorie. EMC - Neurologia 2008;8:1-23. [DOI: 10.1016/s1634-7072(08)70522-1] [Reference Citation Analysis]
282 Dalmau J, Rosenfeld M. Paraneoplastic Neurologic Syndromes. Abeloff's Clinical Oncology 2008. [DOI: 10.1016/b978-0-443-06694-8.50055-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
283 Ballow M. Immunoglobulin therapy: replacement and immunomodulation. Clinical Immunology 2008. [DOI: 10.1016/b978-0-323-04404-2.10085-5] [Reference Citation Analysis]
284 Rosenfeld MR, Dalmau J. Cancer and the Nervous System. Neurology in Clinical Practice 2008. [DOI: 10.1016/b978-0-7506-7525-3.50083-2] [Reference Citation Analysis]
285 Wortmann RL. Idiopathic Inflammatory Myopathies. Primer on the Rheumatic Diseases 2008. [DOI: 10.1007/978-0-387-68566-3_18] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
286 Hwang V. Muscle and Connective Tissue Disorders. Pediatric Emergency Medicine 2008. [DOI: 10.1016/b978-141600087-7.50100-8] [Reference Citation Analysis]
287 Selva O’callaghan A, Trallero Araguás E. Inflammatory Myopathies. Dermatomyositis, Polymyositis, and Inclusion Body Myositis. Reumatología Clínica (English Edition) 2008;4:197-206. [DOI: 10.1016/s2173-5743(08)70187-4] [Reference Citation Analysis]
288 Francès C. Dermatomyosite. Manifestations dermatologiques des connectivites, vasculites et affections systémiques apparentées. [DOI: 10.1007/978-2-287-33886-1_5] [Reference Citation Analysis]
289 Richter J, Iking-Konert C. [Current treatments of dermatomyositis and polymyositis]. Z Rheumatol 2007;66:686-92. [PMID: 17999071 DOI: 10.1007/s00393-007-0226-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
290 Norwood F, Rose MR. Muscle Disorders. Evidence-based Neurology: Management of Neurological Disorders 2007. [DOI: 10.1002/9780470988350.ch24] [Reference Citation Analysis]
291 Meyer O. Maladies Systémiques et Rhumatismes Inflammatoires (Hors PR, SpA et arthropathies métaboliques). Revue du Rhumatisme 2007;74:29-41. [DOI: 10.1016/s1169-8330(07)80610-7] [Reference Citation Analysis]
292 Volc-platzer B. Dermatomyositis und Polymyositis. Medizinische Therapie 2007 | 2008. [DOI: 10.1007/978-3-540-48554-4_14] [Reference Citation Analysis]
293 Benveniste O, Pavy S, Maisonobe T, Dubourg O, Herson S. Actualités des myopathies inflammatoires: nouvelles classifications, critères diagnostiques, histopathologie, et traitements. Revue du Rhumatisme 2007;74:774-782. [DOI: 10.1016/j.rhum.2007.05.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
294 Dalmau J. Paraneoplastic disorders of the nervous system. European Journal of Cancer Supplements 2007;5:53-67. [DOI: 10.1016/s1359-6349(07)70023-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
295 Ringel I, Zettl UK. Intravenous immunoglobulin therapy in neurological diseases during pregnancy. J Neurol 2006;253 Suppl 5:V70-4. [PMID: 16998758 DOI: 10.1007/s00415-006-5012-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
296 Rafailidis PI, Kapaskelis A, Falagas ME. Periorbital and facial swelling due to dermatomyositis. CMAJ 2007;176:1580-1. [PMID: 17515583 DOI: 10.1503/cmaj.061205] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
297 Negi VS, Elluru S, Sibéril S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007;27:233-245. [PMID: 17351760 DOI: 10.1007/s10875-007-9088-9] [Cited by in Crossref: 191] [Cited by in F6Publishing: 199] [Article Influence: 11.9] [Reference Citation Analysis]
298 Blockmans D, Houssiau F. New treatment options in systemic diseases. Acta Clin Belg 2007;62:77-82. [PMID: 17547287 DOI: 10.1179/acb.2007.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
299 Sherer Y, Shepshelovich D, Shalev T, Haviv Y, Segal E, Ehrenfeld M, Levy Y, Pauzner R, Shoenfeld Y, Langevitz P. Outcome of patients having dermatomyositis admitted to the intensive care unit. Clin Rheumatol 2007;26:1851-5. [PMID: 17332975 DOI: 10.1007/s10067-007-0588-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
300 Barbasso Helmers S, Dastmalchi M, Alexanderson H, Nennesmo I, Esbjörnsson M, Lindvall B, Lundberg IE. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. Ann Rheum Dis 2007;66:1276-83. [PMID: 17277004 DOI: 10.1136/ard.2006.058644] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
301 Kato S, Morimoto S, Hiramitsu S, Uemura A, Ohtsuki M, Kato Y, Miyagishima K, Mori N, Hishida H. Successful high-dose intravenous immunoglobulin therapy for a patient with fulminant myocarditis. Heart Vessels 2007;22:48-51. [PMID: 17285446 DOI: 10.1007/s00380-006-0923-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
302 Katirji B. Case 20. Electromyography in Clinical Practice 2007. [DOI: 10.1016/b978-0-323-02899-8.50029-x] [Reference Citation Analysis]
303 Dereure O. Inmunoglobulinas intravenosas. EMC - Dermatología 2007;41:1-6. [DOI: 10.1016/s1761-2896(07)70363-1] [Reference Citation Analysis]
304 Dereure O. Immunoglobulines intraveineuses. EMC - Dermatologie 2007;2:1-6. [DOI: 10.1016/s0246-0319(07)41099-8] [Reference Citation Analysis]
305 Cordeiro AC, Isenberg DA. Treatment of inflammatory myopathies. Postgrad Med J 2006;82:417-24. [PMID: 16822917 DOI: 10.1136/pgmj.2005.038455] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
306 Choy E. Myositis. Medicine 2006;34:489-92. [DOI: 10.1053/j.mpmed.2006.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
307 Ytterberg SR. Treatment of refractory polymyositis and dermatomyositis. Curr Rheumatol Rep 2006;8:167-73. [PMID: 16901073 DOI: 10.1007/s11926-996-0021-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
308 Pilkington CA, Wedderburn LR. Paediatric idiopathic inflammatory muscle disease: recognition and management. Drugs 2005;65:1355-65. [PMID: 15977968 DOI: 10.2165/00003495-200565100-00004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]
309 Amato AA, Greenberg SA. INFLAMMATORY MYOPATHIES. CONTINUUM: Lifelong Learning in Neurology 2006;12:140-168. [DOI: 10.1212/01.con.0000290466.34703.26] [Reference Citation Analysis]
310 Traufeller K, Zierz S. Entzündliche, endokrine und toxische Muskelerkrankungen. Klinische Neurologie. [DOI: 10.1007/3-540-31176-9_11] [Reference Citation Analysis]
311 Volc-platzer B. Dermatomyositis und Polymyositis. Medizinische Therapie 2005|2006. [DOI: 10.1007/3-540-27385-9_14] [Reference Citation Analysis]
312 Cherin P. Polymyosites et dermatomyosites. EMC - Appareil locomoteur 2006;1:1-10. [DOI: 10.1016/s0246-0521(03)00139-6] [Reference Citation Analysis]
313 Dalakas MC. Dermatomyositis. Handbook of Systemic Autoimmune Diseases 2006. [DOI: 10.1016/s1571-5078(05)05011-7] [Reference Citation Analysis]
314 Yu K, Yang C, Wu Y, Chu C, Hsueh C. Diffuse Alveolar Damage as the Initial Presentation of Dermatomyositis and Successfully Treated with Intravenous Immunoglobulin and Steroids: A Case Report. Journal of Musculoskeletal Pain 2006;14:45-50. [DOI: 10.1300/j094v14n01_07] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
315 Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005;142:1-11. [PMID: 16178850 DOI: 10.1111/j.1365-2249.2005.02834.x] [Cited by in Crossref: 201] [Cited by in F6Publishing: 224] [Article Influence: 11.2] [Reference Citation Analysis]
316 Li N, Zhao M, Hilario-Vargas J, Prisayanh P, Warren S, Diaz LA, Roopenian DC, Liu Z. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005;115:3440-50. [PMID: 16284651 DOI: 10.1172/JCI24394] [Cited by in Crossref: 192] [Cited by in F6Publishing: 196] [Article Influence: 10.7] [Reference Citation Analysis]
317 Stojkovic T, Dubucquoi S. [The use of intravenous immunoglobulins in neurology]. Rev Neurol (Paris) 2005;161:781-94. [PMID: 16244560 DOI: 10.1016/s0035-3787(05)85137-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
318 Illa I. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. J Neurol 2005;252 Suppl 1:I14-8. [PMID: 15959667 DOI: 10.1007/s00415-005-1104-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
319 Callen JP. Dermatomyositis. Autoimmune Diseases of the Skin. [DOI: 10.1007/3-211-27377-8_11] [Reference Citation Analysis]
320 Bunyan R. Intravenous Immunoglobulin in the Treatment of Peripheral Neuropathy. Neurological Disease and Therapy 2005. [DOI: 10.1201/b14157-42] [Reference Citation Analysis]
321 Bromberg MB. Advances in Diagnosis and Management of Inflammatory Myopathies. Journal of Clinical Neuromuscular Disease 2005;6:167-179. [DOI: 10.1097/01.cnd.0000167480.39597.95] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
322 Michels H, Burmester GR, Buttgereit F. [Intravenous immunoglobulins in chronic idiopathic myositis]. Z Rheumatol 2005;64:102-10. [PMID: 15793676 DOI: 10.1007/s00393-005-0695-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
323 Schäfer J, Reichmann H. Entzündliche Muskelerkrankungen. Neurologie 2005. [DOI: 10.1016/b978-343723390-6.50064-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
324 Eibl M, Wolf H. Immunglobulintherapie. Pädiatrische Allergologie und Immunologie 2005. [DOI: 10.1016/b978-343721311-3.50045-8] [Reference Citation Analysis]
325 Cherin P. Inflammatory myopathies. Acta Clin Belg 2004;59:290-9. [PMID: 15641400 DOI: 10.1179/acb.2004.043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
326 Park IW, Suh YJ, Han JH, Shin YS, Choi JH, Park HS, Suh CH. Dermatomyositis developing in the first trimester of pregnancy. Korean J Intern Med 2003;18:196-8. [PMID: 14619391 DOI: 10.3904/kjim.2003.18.3.196] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
327 Londoño García ÁM. Dermatomiositis. Piel 2004;19:191-199. [DOI: 10.1016/s0213-9251(04)72830-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
328 Ruetter A, Luger TA. Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view. Am J Clin Dermatol 2004;5:153-60. [PMID: 15186194 DOI: 10.2165/00128071-200405030-00003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 1.6] [Reference Citation Analysis]
329 Poullin P, Lefevre P. Médicaments dérivés du plasma. EMC - Anesthésie-Réanimation 2004;1:1-13. [DOI: 10.1016/s0246-0289(02)00067-1] [Reference Citation Analysis]
330 Pongratz D. Entzündliche Muskelkrankheiten aus der Sicht des Neurologen. Neuroorthopädie 2004. [DOI: 10.1007/978-3-7985-1949-7_21] [Reference Citation Analysis]
331 Pongratz D. [Importance of inflammatory myopathies in practice]. Schmerz 2003;17:432-6. [PMID: 14648316 DOI: 10.1007/s00482-003-0255-5] [Reference Citation Analysis]
332 Cook IJ. Treatment of Oropharyngeal Dysphagia. Curr Treat Options Gastroenterol. 2003;6:273-281. [PMID: 12846936 DOI: 10.1007/s11938-003-0019-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
333 Simon HU, Späth PJ. IVIG--mechanisms of action. Allergy 2003;58:543-52. [PMID: 12823109 DOI: 10.1034/j.1398-9995.2003.00239.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 92] [Article Influence: 4.3] [Reference Citation Analysis]
334 Burkhardt H, Kalden JR. Autoimmune Disease: Treatment. eLS 2003. [DOI: 10.1038/npg.els.0001437] [Reference Citation Analysis]
335 Hartung H, Ritz M, Steck A. Elemente der Neuroimmunologie. Demyelinisierende Erkrankungen 2003. [DOI: 10.1007/978-3-642-57441-2_2] [Reference Citation Analysis]
336 Briemberg HR, Amato AA. Chapter 20 Inflammatory myopathies. Handbook of Clinical Neurophysiology 2003. [DOI: 10.1016/s1567-4231(09)70130-3] [Reference Citation Analysis]
337 Pongratz D. Entzündliche Muskelkrankheiten. Chronischer Muskelschmerz 2003. [DOI: 10.1007/978-3-7985-1965-7_2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
338 Gómez-puerta J, Cucho Venegas M, Cervera Segura R, Font Franco J. Inmunoglobulinas endovenosas en las enfermedades autoinmunes sistémicas. Revista Clínica Española 2003;203:548-554. [DOI: 10.1016/s0014-2565(03)71352-6] [Reference Citation Analysis]
339 Swenson MR. Neuroimmunology. Atlas of Clinical Neurology 2003. [DOI: 10.1007/978-1-4757-4552-8_13] [Reference Citation Analysis]
340 Dalakas MC, Pongratz D. Inflammatory Myopathies. Neurological Disorders 2003. [DOI: 10.1016/b978-012125831-3/50290-2] [Reference Citation Analysis]
341 Jablonska S, Blaszczyk M. Dermatomyositis. European Handbook of Dermatological Treatments 2003. [DOI: 10.1007/978-3-662-07131-1_21] [Reference Citation Analysis]
342 Cherin P. Polimiositis y dermatomiositis. EMC - Aparato Locomotor 2003;36:1-11. [DOI: 10.1016/s1286-935x(03)72284-9] [Reference Citation Analysis]
343 Dalmau J, Graus F. Paraneoplastic Syndromes. Office Practice of Neurology 2003. [DOI: 10.1016/b0-44-306557-8/50180-5] [Reference Citation Analysis]
344 Downes SJ, Stahlman JE, Borras IM, Salmun LM, Schneider LC. Open-Label Trial of High-Dose Intravenous Immunoglobulin in Patients with Severe Asthma. Pediatric Asthma, Allergy & Immunology 2002;15:187-194. [DOI: 10.1089/088318702320323091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
345 Choy E. Myositis. Medicine 2002;30:42-4. [DOI: 10.1383/medc.30.10.42.28257] [Reference Citation Analysis]
346 Oddis CV. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Curr Rheumatol Rep 2002;4:401-2. [PMID: 12217244 DOI: 10.1007/s11926-002-0084-z] [Reference Citation Analysis]
347 Wiles CM, Brown P, Chapel H, Guerrini R, Hughes RA, Martin TD, McCrone P, Newsom-Davis J, Palace J, Rees JH, Rose MR, Scolding N, Webster AD. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry 2002;72:440-8. [PMID: 11909900 DOI: 10.1136/jnnp.72.4.440] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
348 Danieli MG, Malcangi G, Palmieri C, Logullo F, Salvi A, Piani M, Danieli G. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 2002;61:37-41. [PMID: 11779756 DOI: 10.1136/ard.61.1.37] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 3.9] [Reference Citation Analysis]
349 Orfanos CE, Garbe C. Dermatomyositis. Therapie der Hautkrankheiten 2002. [DOI: 10.1007/978-3-642-56219-8_22] [Reference Citation Analysis]
350 Amato AA, Dumitru D. Acquired Myopathies. Elextrodiagnostic Medicine 2002. [DOI: 10.1016/b978-1-56053-433-4.50036-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
351 Rohkamm R. Muskelerkrankungen und neuromuskuläre Störungen. Neurologische Therapie 2002. [DOI: 10.1007/978-3-642-56398-0_22] [Reference Citation Analysis]
352 Poullin P, Lefevre P. Medicamentos derivados del plasma. EMC - Anestesia-Reanimación 2002;28:1-11. [DOI: 10.1016/s1280-4703(02)71821-5] [Reference Citation Analysis]
353 Wada J, Shintani N, Kikutani K, Nakae T, Yamauchi T, Takechi K. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition. Clin Exp Immunol 2001;124:282-9. [PMID: 11422206 DOI: 10.1046/j.1365-2249.2001.01499.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.1] [Reference Citation Analysis]
354 Patel SY, Kumararatne DS. From black magic to science: understanding the rationale for the use of intravenous immunoglobulin to treat inflammatory myopathies. Clin Exp Immunol. 2001;124:169-171. [PMID: 11422191 DOI: 10.1046/j.1365-2249.2001.01565.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
355 Gold R, Späth P. Wirkmechanismen von Immunglobulinen. Immunglobuline in der klinischen Neurologie 2001. [DOI: 10.1007/978-3-642-93716-3_2] [Reference Citation Analysis]
356 Duong Van Huyen J, Chevalier J, Kazatchkine MD, Kaveri S. Modulation of Endothelial Cell Function by Normal Polyspecific Human Immunoglobulins (IVIg). Atherosclerosis and Autoimmunity 2001. [DOI: 10.1016/b978-044450669-6/50027-x] [Reference Citation Analysis]
357 Lindner A, Zierz S. Polymyositis, Dermatomyositis, Einschlusskörpermyositis und okuläre Myositis. Immunglobuline in der klinischen Neurologie 2001. [DOI: 10.1007/978-3-642-93716-3_4] [Reference Citation Analysis]
358 Mantegazza R, Antozzi C, Cornelio F, Di Donato S. Chapter 15 Clinical Trials in Muscle Disorders. Clinical Trials in Neurologic Practice 2001. [DOI: 10.1016/s1877-3419(09)70022-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
359 Callen JP. Dermatomyositis. Autoimmune Diseases of the Skin 2001. [DOI: 10.1007/978-3-7091-3704-8_6] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
360 Grisold W, Drlicek M, Urbanits S. Paraneoplastische neurologische Syndrome. Immunglobuline in der klinischen Neurologie 2001. [DOI: 10.1007/978-3-642-93716-3_11] [Reference Citation Analysis]
361 Orrell RW, Guiloff RJ. Myopathies: Ethics, Outcome Variables and Clinical Scales. Clinical Trials in Neurology 2001. [DOI: 10.1007/978-1-4471-3787-0_40] [Reference Citation Analysis]
362 Jayne D. Intravenous immunoglobulin as immuno-modifying treatment. Disease-modifying Therapy in Vasculitides 2001. [DOI: 10.1007/978-3-0348-8235-4_5] [Reference Citation Analysis]
363 Schuler G, Schuler-thurner B. Intravenöse Immunglobulintherapie. Fortschritte der praktischen Dermatologie und Venerologie 2001. [DOI: 10.1007/978-3-642-56437-6_65] [Reference Citation Analysis]
364 Burmester G, Buttgereit F. Dermatomyositis — Polymyositis (M 33). Interdisziplinäre klinische Rheumatologie 2001. [DOI: 10.1007/978-3-662-07967-6_66] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
365 Roger P, Fouché R, Tiger F, Vandenbos F, Bernardin G, Fuzibet J, Perrin C, Michiels J, Dellamonica P, Mattéi M. Myosites inflammatoires en réanimation Á propos de trois cas. Réanimation Urgences 2000;9:580-584. [DOI: 10.1016/s1164-6756(00)90067-7] [Reference Citation Analysis]
366 Dantas M, Costa RS, Barbosa JE, Graeff MS, Sarti W, De Carvalho IF. Intravenous immunoglobulin (IVIG) attenuates antibody binding in acute haemorrhagic immunopneumonitis in a rat model of complement-dependent lung injury. Clin Exp Immunol 2000;121:139-45. [PMID: 10886251 DOI: 10.1046/j.1365-2249.2000.01252.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
367 Seth V, Kabra SK, Semwal OP, Jain Y. Juvenile dermatomyositis. Indian J Pediatr 1996;63:375-9. [PMID: 10830014 DOI: 10.1007/BF02751533] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
368 Olek MJ, Khoury SJ. Multiple Sclerosis. Women and Health 2000. [DOI: 10.1016/b978-012288145-9/50063-2] [Reference Citation Analysis]
369 Jablonska S. Dermatomyositis. European Handbook of Dermatological Treatments 2000. [DOI: 10.1007/978-3-662-03835-2_22] [Reference Citation Analysis]
370 Eibl MM. Immunglobulintherapie bei Patienten mit Lungenerkrankungen. Pharmakotherapie bronchopulmonaler Erkrankungen 2000. [DOI: 10.1007/978-3-7091-6761-8_20] [Reference Citation Analysis]
371 Rabinovitch N, Gelfand EW, Leung DY. The role of immunoglobulin therapy in allergic diseases. Allergy 1999;54:662-8. [PMID: 10442521 DOI: 10.1034/j.1398-9995.1999.00094.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
372 Mastaglia FL, Phillips BA, Zilko PJ. Inflammatory Myopathy. Curr Treat Options Neurol 1999;1:263-72. [PMID: 11096714 DOI: 10.1007/s11940-999-0008-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
373 Felber WM, Damian M, Stingele R, Hansen H. Neuromuskuläre Erkrankungen. Neurologische Intensivmedizin 1999. [DOI: 10.1007/978-3-642-58415-2_39] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
374 Bar-dayan Y, Kaveri SV, Bar-dayan Y, Pashov A, Shoenfeld Y, Kazatchkine MD. Anti-Inflammatory Effects of Intravenous Immunoglobulin. Symposium in Immunology VIII 1999. [DOI: 10.1007/978-3-642-59947-7_11] [Reference Citation Analysis]
375 Bröcker E. Therapie dermatologischer Symptome bei Tumorpatienten. Vorträge und Dia-Klinik der 16. Fortbildungswoche 1998 Fortbildungswoche für Praktische Dermatologie und Venerologie e.V. c/o Klinik und Poliklinik für Dermatologie und Allergologie Ludwig-Maximilians-Universität München in Verbindung mit dem Berufsverband der Deutschen Dermatologen e.V. 1999. [DOI: 10.1007/978-3-662-01058-7_43] [Reference Citation Analysis]
376 Xu C, Poirier B, Duong Van Huyen JP, Lucchiari N, Michel O, Chevalier J, Kaveri S. Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases. Am J Pathol 1998;153:1257-66. [PMID: 9777957 DOI: 10.1016/S0002-9440(10)65670-2] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 2.6] [Reference Citation Analysis]
377 van Engelen BG, Benders AA, Wevers RA, Gabreëls FJ, Renier WO, Veerkamp JH. Intravenous immunoglobulin preparation increases myoplasmic calcium concentration by activating the dihydropyridine-ryanodine receptor complex. J Neurol Sci 1998;156:35-40. [PMID: 9559984 DOI: 10.1016/s0022-510x(98)00022-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
378 Kagen LJ. Confounding factors in the management of myositis. Hosp Pract (1995) 1997;32:151-3, 157-9, 162. [PMID: 9275968 DOI: 10.1080/21548331.1997.11443548] [Reference Citation Analysis]
379 Messer G, Meurer M. High-Dose Intravenous Immunoglobulins. Strategies for Immunointerventions in Dermatology 1997. [DOI: 10.1007/978-3-642-60752-3_13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
380 Kumamoto T, Abe T, Ueyama H, Sugihara R, Shigenaga T, Tsuda T. Elevated soluble intercellular adhesion molecules-1 in inflammatory myopathy. Acta Neurol Scand 1997;95:34-7. [PMID: 9048983 DOI: 10.1111/j.1600-0404.1997.tb00065.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
381 Otten A, Vermeulen M, Bossuyt PM, Otten A. Intravenous immunoglobulin treatment in neurological diseases. J Neurol Neurosurg Psychiatry 1996;60:359-61. [PMID: 8774395 DOI: 10.1136/jnnp.60.4.359] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
382 Cavalieri S, Rotoli M, Cerimele D. Treatment of dermatomyositis with intravenous immunoglobulin. Journal of Dermatological Treatment 1996;7:115-117. [DOI: 10.3109/09546639609089543] [Reference Citation Analysis]
383 Mueller-eckhardt C. Therapie mit Immunglobulinen. Transfusionsmedizin 1996. [DOI: 10.1007/978-3-662-10599-3_26] [Reference Citation Analysis]
384 Lissner R, Mondorf AW. Störungen des Immunsystems. Klinische Pharmakologie 1996. [DOI: 10.1007/978-3-642-97796-1_47] [Reference Citation Analysis]
385 Dalakas MC. Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease. J Clin Immunol 1995;15:70S-5S. [PMID: 8613495 DOI: 10.1007/BF01540896] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 0.7] [Reference Citation Analysis]
386 Zeuner RA, Schroeder JO, Schröder F, Euler HH. Successful application of high dose intravenous immunoglobulins in Sjögren's syndrome associated arthritis. Ann Rheum Dis 1995;54:936. [PMID: 7492248 DOI: 10.1136/ard.54.11.936-a] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
387 Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis--four year review of nine cases. Arch Dis Child 1995;72:25-8. [PMID: 7717731 DOI: 10.1136/adc.72.1.25] [Cited by in Crossref: 86] [Cited by in F6Publishing: 84] [Article Influence: 3.1] [Reference Citation Analysis]
388 Meurer M. Die Therapie der bullösen Dermatosen. Fortschritte der praktischen Dermatologie und Venerologie 1995. [DOI: 10.1007/978-3-642-79156-7_13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
389 Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-35. [PMID: 7962520 DOI: 10.1172/JCI117520] [Cited by in Crossref: 273] [Cited by in F6Publishing: 275] [Article Influence: 9.4] [Reference Citation Analysis]
390 Cherin P, Herson S. Indications for intravenous gammaglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 1994;57 Suppl:50-4. [PMID: 7964854 DOI: 10.1136/jnnp.57.suppl.50] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.6] [Reference Citation Analysis]
391 Coskey RJ. Dermatologic therapy: 1993. J Am Acad Dermatol 1994;31:764-74. [PMID: 7929923 DOI: 10.1016/s0190-9622(94)70239-x] [Reference Citation Analysis]